| Name | Title | Contact Details |
|---|
Antibody and protein biotherapeutics are changing the way physicians treat autoimmune diseases, asthma, and cancer. At Xencor, we apply proprietary protein engineering technologies to develop better biotherapeutics – antibodies that target new biological mechanisms and are more potent, safer and longer lasting – to improve patient outcomes and quality of life. Our XmAb antibody engineering technology dramatically augments natural antibody immune functions while maintaining over 99.5% identity to natural antibodies. This combination of new, highly potent activities while maintaining the beneficial drug features and simplicity of natural antibodies allows us to create differentiated drug candidates with potential for breakthrough performance. The XmAb® platform has resulted in a robust pipeline of antibody product candidates, including eight in human clinical trials being developed by Xencor and by pharmaceutical partners. Xencor is also discovering biologics products that improve the performance of old antibody drugs, known as biosuperiors, to benefit patients, ease compliance and help reduce costs.
Find out who raised funds! Daily updated. SEC filings of fundraisings and investments in hedge funds, startups and private equity companies.
dp murphy co inc is a Deer Park, NY-based company in the Business Services sector.
HEED – a new generation of event experiences – transforms the sights, sounds, and emotions of live events to immerse fans in the action, revolutionizing the way fans connect with their favorite talent, teams and brands.
ACT Group is a Minneapolis, MN-based company in the Business Services sector.